MilliporeSigma Collaborates with iCON™ to Offer BioReliance® End-to-End Turnkey Modular MAb Manufacturing Platform
MilliporeSigma today announced a collaboration with IPS-Integrated Project Services, LLC and G-CON Manufacturing, Inc. to provide the most advanced 2,000L monoclonal antibody (MAb) facility and single-use ...
- Speeds access to biologics worldwide
- Extends MilliporeSigma's BioReliance® End-to-End offering
Burlington, Massachusetts, December 20, 2017 – MilliporeSigma today announced a collaboration with IPS-Integrated Project Services, LLC and G-CON Manufacturing, Inc. to provide the most advanced 2,000L monoclonal antibody (MAb) facility and single-use process technology platform. The deal will extend MilliporeSigma's BioReliance® End-to-End offering by integrating MilliporeSigma’s single-use process equipment, end-to-end process development capabilities and cGMP manufacturing experience into the iCON™ facility design platform, for a true turnkey modular facility solution.
“Biologics are helping to fight some of the toughest diseases worldwide, and demand for these therapies continues to grow,” said Andrew Bulpin, Head of Process Solutions at MilliporeSigma. “This collaboration is an innovative concept built upon MilliporeSigma’s years of experience in designing, constructing and running cGMP biologics production, combined with the iCON™ facility, team and design platform. It will decrease time-to-market and accelerate access to biologics to improve the lives of patients around the world.”
The integrated end-to-end offering will deliver an innovative platform for fast and flexible deployment of 2,000L MAb production facilities. The hallmarks of the combined solution will include pre-fabricated cleanroom units, a structural platform based on cost-effective pre-engineered building delivery, bioprocess and single-use equipment expertise, as well as turnkey facilities capable of fast-track deployment.
This collaboration extends MilliporeSigma's BioReliance® End-to-End offering — a comprehensive suite of products and services that help biopharmaceutical companies accelerate the progression of molecules into the clinic and toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization.
iCON-Collaboration-to-Offer-BioReliance-End-to-End-Turnkey- Modular- MAb-Manufacturing-Platform-US.PDF
Caption (iCON): MilliporeSigma's collaboration with iCON ™ will decrease time-to-market and accelerate access to biologics to improve the lives of patients around the world
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has five businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials – and generated sales of €15 billion in 2016. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany Highlights Commitment to Improving Cancer Outcomes ...
Merck KGaA, Darmstadt, Germany, announced 43 abstracts covering modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US.